Information Provided By:
Fly News Breaks for March 31, 2015
ASPX, TEVA, CNCE
Mar 31, 2015 | 14:10 EDT
Ladenburg said Teva's (TEVA) deal for Auspex (ASPX) results in a payment of approximately $50M to Concert Pharmaceuticals (CNCE) related to a licensing pact signed in 2011 while it also "underscores and validates" the potential of deuterium-based chemistry. The firm maintains its Buy rating and $26 price target on Concert shares.
News For CNCE;TEVA;ASPX From the Last 2 Days
There are no results for your query CNCE;TEVA;ASPX